CA3240074A1 - Inhibitors of menin-mll interaction - Google Patents
Inhibitors of menin-mll interaction Download PDFInfo
- Publication number
- CA3240074A1 CA3240074A1 CA3240074A CA3240074A CA3240074A1 CA 3240074 A1 CA3240074 A1 CA 3240074A1 CA 3240074 A CA3240074 A CA 3240074A CA 3240074 A CA3240074 A CA 3240074A CA 3240074 A1 CA3240074 A1 CA 3240074A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- solvate
- acceptable salt
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287716P | 2021-12-09 | 2021-12-09 | |
| US63/287,716 | 2021-12-09 | ||
| US202263306399P | 2022-02-03 | 2022-02-03 | |
| US63/306,399 | 2022-02-03 | ||
| US202263397322P | 2022-08-11 | 2022-08-11 | |
| US63/397,322 | 2022-08-11 | ||
| PCT/US2022/052404 WO2023107696A2 (en) | 2021-12-09 | 2022-12-09 | Inhibitors of menin-mll interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3240074A1 true CA3240074A1 (en) | 2023-06-15 |
Family
ID=86731242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3240074A Pending CA3240074A1 (en) | 2021-12-09 | 2022-12-09 | Inhibitors of menin-mll interaction |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20250163061A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4444300A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024545184A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240117133A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118647378A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022405438A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3240074A1 (cg-RX-API-DMAC7.html) |
| JO (1) | JOP20240130A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2024007069A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202529770A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023107696A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202529770A (zh) * | 2021-12-09 | 2025-08-01 | 美商巴拉療法公司 | 梅嫩蛋白（ｍｅｎｉｎ）－ＭＬＬ相互作用之抑制劑 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016197027A1 (en) * | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| BR112018012707A2 (pt) * | 2015-12-22 | 2019-01-29 | Vitae Pharmaceuticals Inc | inibidores da interação de menin-mll |
| TW201920170A (zh) * | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| TW202529770A (zh) * | 2021-12-09 | 2025-08-01 | 美商巴拉療法公司 | 梅嫩蛋白（ｍｅｎｉｎ）－ＭＬＬ相互作用之抑制劑 |
-
2022
- 2022-12-08 TW TW113134963A patent/TW202529770A/zh unknown
- 2022-12-09 CN CN202280090933.7A patent/CN118647378A/zh active Pending
- 2022-12-09 US US18/717,973 patent/US20250163061A1/en active Pending
- 2022-12-09 WO PCT/US2022/052404 patent/WO2023107696A2/en not_active Ceased
- 2022-12-09 KR KR1020247022800A patent/KR20240117133A/ko active Pending
- 2022-12-09 MX MX2024007069A patent/MX2024007069A/es unknown
- 2022-12-09 AU AU2022405438A patent/AU2022405438A1/en active Pending
- 2022-12-09 JP JP2024534648A patent/JP2024545184A/ja active Pending
- 2022-12-09 CA CA3240074A patent/CA3240074A1/en active Pending
- 2022-12-09 KR KR1020257029621A patent/KR20250135350A/ko active Pending
- 2022-12-09 EP EP22905177.6A patent/EP4444300A4/en active Pending
-
2024
- 2024-06-07 MX MX2025012108A patent/MX2025012108A/es unknown
- 2024-06-10 JO JOJO/P/2024/0130A patent/JOP20240130A1/ar unknown
-
2025
- 2025-08-21 JP JP2025137487A patent/JP2025170331A/ja active Pending
- 2025-09-09 AU AU2025230651A patent/AU2025230651A1/en active Pending
- 2025-09-19 US US19/334,801 patent/US20260022120A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024545184A (ja) | 2024-12-05 |
| JOP20240130A1 (ar) | 2024-06-10 |
| US20260022120A1 (en) | 2026-01-22 |
| US20250163061A1 (en) | 2025-05-22 |
| KR20250135350A (ko) | 2025-09-12 |
| CN118647378A (zh) | 2024-09-13 |
| WO2023107696A3 (en) | 2023-07-27 |
| AU2022405438A1 (en) | 2024-06-20 |
| AU2025230651A1 (en) | 2025-09-25 |
| EP4444300A4 (en) | 2026-03-18 |
| MX2024007069A (es) | 2024-08-22 |
| TW202529770A (zh) | 2025-08-01 |
| JP2025170331A (ja) | 2025-11-18 |
| MX2025012108A (es) | 2025-11-03 |
| KR20240117133A (ko) | 2024-07-31 |
| WO2023107696A2 (en) | 2023-06-15 |
| EP4444300A2 (en) | 2024-10-16 |
| TW202337435A (zh) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7505023B2 (ja) | 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤 | |
| AU2022200741B2 (en) | Aminothiazole compounds as c-Kit inhibitors | |
| CN112778276B (zh) | 作为shp2抑制剂的化合物及其应用 | |
| US12486276B2 (en) | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | |
| WO2025085580A1 (en) | Kras(g12d) inhibitors | |
| CA3047107A1 (en) | Benzimidazole compounds as c-kit inhibitors | |
| CA3051206A1 (en) | Bicyclic compounds as allosteric shp2 inhibitors | |
| ES3062921T3 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
| CN111343988A (zh) | 作为ehmt2抑制剂的胺取代的杂环化合物及其衍生物 | |
| CN108948019B (zh) | 黏着斑激酶抑制剂及其用途 | |
| WO2023245166A2 (en) | Compounds for treatment of a coronavirus infection | |
| JP2023545219A (ja) | Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための７－アザインドール化合物 | |
| US20250282795A1 (en) | EGFR Inhibitors in cancer treatment | |
| AU2023382489A1 (en) | Inhibitors of tyk2 | |
| US20240246966A1 (en) | NEW PYRAZOLO[1,5-a] PYRIMIDINE DERIVATIVES AS SIGMA LIGANDS | |
| EP4416151A1 (en) | Chimeric compounds useful in treating diseases | |
| US20250163061A1 (en) | Inhibitors of menin-mll interaction | |
| EP3965749A1 (en) | Inhibiting usp19 | |
| WO2025175258A1 (en) | Inhibitors of cdk2 | |
| WO2025175264A1 (en) | Inhibitors of cdk2 | |
| WO2025251058A1 (en) | Egfr inhibitors in cancer treatment | |
| AU2023408571A1 (en) | Inhibitors of jak2 | |
| AU2024294043A1 (en) | Glutarimide isoindolinone skeleton-based compound | |
| EA052590B1 (ru) | Молекулы protac белка malt1 | |
| US20250066358A1 (en) | Inhibitors of Menin-MLL Interaction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241001 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241107 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241107 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250909 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250909 |